OTCMKTS:EVTCY Evotec (EVTCY) Stock Price, News & Analysis $4.11 +0.07 (+1.73%) As of 01/17/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartFinancialsHeadlinesSEC Filings About Evotec Stock (OTCMKTS:EVTCY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Evotec alerts:Sign Up Key Stats Today's Range$4.09▼$4.1450-Day Range$4.04▼$5.5552-Week Range$14.22▼$26.57Volume24,244 shsAverage Volume2,407 shsMarket Capitalization$1.36 billionP/E Ratio10.02Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEvotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.Read More… Receive EVTCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter. Email Address EVTCY Stock News HeadlinesHalozyme withdraws $2.1 billion buyout offer for German drug developer EvotecNovember 25, 2024 | finance.yahoo.comEQS-News: Evotec SE reports 9M 2024 results: Strategic Progress and Successful Expansion Amid Challenging Market ConditionsNovember 6, 2024 | markets.businessinsider.comDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute he steps back into the White House. Because if what’s in this leaked document is even half true (and trust me, it comes from a very, very credible source)... Trump’s first Executive Order would easily be the boldest, most mind-blowing and daring American initiative ANY U.S. President has launched in over 80 years. January 22, 2025 | Banyan Hill Publishing (Ad)Evotec SE: Just - Evotec Biologics Opens Cutting-Edge Biologics Facility - J.POD Toulouse, FranceSeptember 20, 2024 | finanznachrichten.deAnalysts Have Been Trimming Their Evotec SE (ETR:EVT) Price Target After Its Latest ReportAugust 17, 2024 | uk.finance.yahoo.comEvotec SE (NASDAQ:EVO) Q2 2024 Earnings Call TranscriptAugust 15, 2024 | msn.comEvotec SE: Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers SquibbAugust 8, 2024 | finanznachrichten.deEQEvotec SE Appoints Dr Christian Wojczewski as Chief Executive OfficerApril 24, 2024 | finance.yahoo.comSee More Headlines EVTCY Stock Analysis - Frequently Asked Questions How have EVTCY shares performed this year? Evotec's stock was trading at $4.16 at the beginning of the year. Since then, EVTCY shares have decreased by 1.2% and is now trading at $4.11. View the best growth stocks for 2025 here. When did Evotec's stock split? Evotec shares split on Wednesday, October 20th 2021. The 3-1 split was announced on Wednesday, October 20th 2021. The newly minted shares were payable to shareholders after the closing bell on Wednesday, October 20th 2021. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. Does Evotec have any subsidiaries? Evotec subsidiaries include Central Glass Germany. GmbH, Central Glass Germany, Rigenerand Srl, GlaxoSmithKine's the Verona site, Just-Evotec Biologics, Aptuit, Cyprotex, and others. How do I buy shares of Evotec? Shares of EVTCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today1/21/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:EVTCY CUSIPN/A CIK1412558 Webwww.evotec.com Phone(494) 056-0810Fax49-40-5608-1222Employees4,200Year Founded1993Profitability EPS (Most Recent Fiscal Year)$0.41 Trailing P/E Ratio10.02 Forward P/E RatioN/A P/E GrowthN/ANet Income$7.14 million Net Margins20.85% Pretax Margin23.90% Return on Equity16.02% Return on Assets7.81% Debt Debt-to-Equity Ratio0.53 Current Ratio2.57 Quick Ratio2.50 Sales & Book Value Annual Sales$572.16 million Price / Sales2.37 Cash Flow$0.04 per share Price / Cash Flow105.53 Book Value$2.52 per share Price / Book1.63Miscellaneous Outstanding Shares330,221,000Free FloatN/AMarket Cap$1.36 billion OptionableNot Optionable Beta0.98 Social Links A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (OTCMKTS:EVTCY) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThe Crypto Secret Wall Street Doesn’t Want You to KnowThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evotec SE Please log in to your account or sign up in order to add this asset to your watchlist. Share Evotec With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.